Alpha Tau Medical Ltd. Warrant (DRTSW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Alpha Tau Medical Ltd. Warrant Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BO Brian Oliveira Clear Street Group Inc. | 62,666 | $21,620 | $240,324.11 | $218,704.11 | 1,011.58% |
| ECM Eisler Capital Management Ltd. Eisler Capital Management Ltd. | 21,775 | $4,572.75 | $79,261 | $74,688.25 | 1,633.33% |
Alpha Tau Medical Ltd. Warrant (DRTSW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alpha Tau Medical Ltd. Warrant ever had a stock split?
Alpha Tau Medical Ltd. Warrant Profile
| Biotechnology Industry | Healthcare Sector | Uzi Sofer CEO | NASDAQ (CM) Exchange | 23321V111 CUSIP |
| IL Country | 121 Employees | - Last Dividend | - Last Split | 8 Mar 2021 IPO Date |
Overview
Alpha Tau Medical Ltd. is a pioneering force in the field of oncology therapeutics, currently in the clinical-stage of developing a revolutionary treatment known as diffusing alpha-emitters radiation therapy (Alpha DaRT). With its focus on targeting solid cancers, the company's research and development efforts span across both Israel and the United States. Established in 2015 and having its headquarters in Jerusalem, Israel, Alpha Tau Medical Ltd. is committed to advancing the fight against cancer through its innovative approach to radiation therapy. By leveraging the unique properties of alpha-emitters, the company aims to provide new hope and solutions for patients battling various forms of solid tumors.
Products and Services
Alpha Tau Medical Ltd. is centered around its proprietary Alpha DaRT technology, which is currently being evaluated through clinical trials and preclinical studies for its efficacy in treating a wide range of solid tumors:
- Skin, Oral, Pancreatic, Prostate, Lung, Liver, and Breast Cancers: These are at the forefront of the company’s clinical trials utilizing Alpha DaRT technology, showcasing its versatility and potential in treating a diverse array of solid tumor types.
- Brain and Other Cancers: Alpha Tau Medical is extending its research to include preclinical or pending clinical studies for brain and various other forms of cancer, highlighting the expansive scope of Alpha DaRT's applicability and its potential to offer benefits across a broader spectrum of oncological challenges.
- Hepatic Cell Carcinoma, Glioblastoma Multiforme, Lung Cancer, and More: The company is also engaged in preclinical studies targeting these specific types of cancer, underscoring its commitment to exploring Alpha DaRT's effectiveness in combating even the most challenging and aggressive forms of solid tumors.
